Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Novel Alkylating Agent Melflufen Displays Potent Efficacy in Plasma Cell Leukemia Samples and Other High-Risk Subtypes of Multiple Myeloma

Beau M Idler, Olivia Perez De Acha, MD, Owen Lockerbie, PhD, Ken Flanagan, PhD, Fredrik Lehmann, MSc, PhD, Peter A Forsberg, MD, Tomer M Mark, MD MS, Daniel W. Sherbenou, MD PhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-138762

Published: 2020

Journal Articles

Myeloma Drug Sensitivity Testing to Optimize Retreatment with Anti-CD38 Monoclonal Antibodies in Daratumumab-Refractory Patients

Olivia Perez De Acha, MD, Beau M Idler, Zachary J Walker, BS, MS, Peter A Forsberg, MD, Tomer M Mark, MD MS, Daniel W. Sherbenou, MD PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137819

Published: 2020

Journal Articles

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Zachary J Walker, BS, MS, Beau M Idler, BA, Michael J VanWyngarden, BS, Brett M. Stevens, PhD, Shelby C Bearrows, BS, Lorraine N Davis, BS, Andrew Hammes, MS, Clayton Smith, MD, Craig T Jordan, PhD, Tomer M Mark, MD MS, Peter A Forsberg, MD, Daniel W Sherbenou, MD PhD

Blood (2019) 134 (Supplement_1): 4404.

https://doi.org/10.1182/blood-2019-121937

Published: 2019

Journal Articles

Chronic Graft Versus Host Disease Burden and Relapse Rates Are Lower with Comparable Overall Survival and Graft Versus Host Disease Free, Relapse Free Survival Following Adult Umbilical Cord Blood Compared to Matched Sibling Peripheral Blood Stem Cell Transplantation

Prashant Sharma, MD, Enkhtsetseg Purev, MD PhD, Bradley M. Haverkos, MD MPH, MS, Daniel A Pollyea, MD, Clayton Smith, MD, Manali Kamdar, Daniel W Sherbenou, MD PhD, Tomer M Mark, MD MS, Peter A Forsberg, MD, Jonathan A Gutman, MD

Blood (2018) 132 (Supplement 1): 4660.

https://doi.org/10.1182/blood-2018-99-119690

Published: 2018

Journal Articles

A Rapid Functional Screen for Small Molecule and Monoclonal Antibody Drug Sensitivity in Multiple Myeloma Patients

Zachary J Walker, MS, Michael J VanWyngarden, BS, Brett M Stevens, PhD, Christophe Langouët-Astrie, MS, Clayton Smith, MD, Brent E Palmer, PhD, Peter A Forsberg, MD, Tomer M Mark, MD MS, Craig T Jordan, PhD, Daniel W Sherbenou, MD PhD

Blood (2018) 132 (Supplement 1): 3203.

https://doi.org/10.1182/blood-2018-99-111394

Published: 2018

Journal Articles

Post-Transplant Diffuse Large B Cell Lymphoma with Non Germinal Center B-Cell Subtype Frequently Lacks Programmed Cell Death Ligand (PD-L1) Overexpression Which May Influence Overall Outcomes

Zohra Nooruddin, MD, Zenggang Pan, MD PhD, Lilyana Gross, Weitzenkamp David, Bradley M. Haverkos, MD MPH, MS, Daniel A Pollyea, MD, Jonathan A Gutman, MD, William Robinson, MD PhD, Clayton Smith, MD FRCPC, Jeffrey Schowinsky, MD, Purev Enkhtsetseg, MD, Daniel W. Sherbenou, MD PhD, Rachel Rabinovitch, MD, Douglas Ney, MD, Craig T Jordan, PhD, Manali Kamdar, MD

Blood (2016) 128 (22): 3054.

https://doi.org/10.1182/blood.V128.22.3054.3054

Published: 2016

Journal Articles

CD46 Is Amplified in High-Risk Myeloma with Gain of Chromosome 1q and Selectively Targeted By a Novel Anti-CD46 Antibody-Drug Conjugate

Daniel W. Sherbenou, MD PhD, Blake T. Aftab, PhD, Yang Su, PhD, Christopher R. Behrens, PhD, Arun P. Wiita, MD PhD, Aaron C. Logan, MD PhD, Diego Acosta-Alvear, PhD, Byron C. Hann, MD PhD, Peter Walter, PhD, Xiaobo Wu, MD, John P. Atkinson, MD, Jeffrey L. Wolf, MD, Thomas G. Martin, III, MD, Bin Liu, PhD

Blood (2016) 128 (22): 384.

https://doi.org/10.1182/blood.V128.22.384.384

Published: 2016

NARROW

Novel Alkylating Agent Melflufen Displays Potent Efficacy in Plasma Cell Leukemia Samples and Other High-Risk Subtypes of Multiple Myeloma

Myeloma Drug Sensitivity Testing to Optimize Retreatment with Anti-CD38 Monoclonal Antibodies in Daratumumab-Refractory Patients

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Chronic Graft Versus Host Disease Burden and Relapse Rates Are Lower with Comparable Overall Survival and Graft Versus Host Disease Free, Relapse Free Survival Following Adult Umbilical Cord Blood Compared to Matched Sibling Peripheral Blood Stem Cell Transplantation

A Rapid Functional Screen for Small Molecule and Monoclonal Antibody Drug Sensitivity in Multiple Myeloma Patients

Post-Transplant Diffuse Large B Cell Lymphoma with Non Germinal Center B-Cell Subtype Frequently Lacks Programmed Cell Death Ligand (PD-L1) Overexpression Which May Influence Overall Outcomes

CD46 Is Amplified in High-Risk Myeloma with Gain of Chromosome 1q and Selectively Targeted By a Novel Anti-CD46 Antibody-Drug Conjugate

Email alerts

ASH Publications

American Society of Hematology

Novel Alkylating Agent Melflufen Displays Potent Efficacy in Plasma Cell Leukemia Samples and Other High-Risk Subtypes of Multiple Myeloma

Myeloma Drug Sensitivity Testing to Optimize Retreatment with Anti-CD38 Monoclonal Antibodies in Daratumumab-Refractory Patients

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Chronic Graft Versus Host Disease Burden and Relapse Rates Are Lower with Comparable Overall Survival and Graft Versus Host Disease Free, Relapse Free Survival Following Adult Umbilical Cord Blood Compared to Matched Sibling Peripheral Blood Stem Cell Transplantation

A Rapid Functional Screen for Small Molecule and Monoclonal Antibody Drug Sensitivity in Multiple Myeloma Patients

Post-Transplant Diffuse Large B Cell Lymphoma with Non Germinal Center B-Cell Subtype Frequently Lacks Programmed Cell Death Ligand (PD-L1) Overexpression Which May Influence Overall Outcomes

CD46 Is Amplified in High-Risk Myeloma with Gain of Chromosome 1q and Selectively Targeted By a Novel Anti-CD46 Antibody-Drug Conjugate

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only